Product Information
NEVIRAPINE 200 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.1472 per EA under NDC 00378405091. Its NADAC has been published 502 times since Nov 28, 2013.
FDA first approved this application on May 22, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378405091
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NEVIRAPINEApproval Type
Generic (ANDA)
FDA Application
ANDA202523FDA Approved
5/22/2012
TE Code
AB
On Market Since
5/22/2012
Pharmacological Classes
Price Statistics
The NADAC for NEVIRAPINE 200 MG TABLET has been published 502 times since Nov 28, 2013, and over the history we have for it it has declined 20.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1472 per EA |
|---|---|
| All-time high | $0.2469 (Sep 13, 2017) |
| All-time low | $0.1122 (Jul 17, 2024) |
| 52-week high | $0.1528 |
| 52-week low | $0.1332 |
| Median price | $0.1506 |
| Average price | $0.1503 |
| Largest weekly change | +45.1% (Jul 18, 2018) |
| Weeks tracked | 502 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the nevirapine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
nevirapine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEVIRAPINE 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NEVIRAPINE 200 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.1472 per EA (NDC 00378405091), effective Sep 30, 2026.
How has the price of NEVIRAPINE 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for NEVIRAPINE 200 MG TABLET has declined 20.1%. It has been tracked across 502 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEVIRAPINE 200 MG TABLET?
Since Nov 28, 2013, the NADAC for NEVIRAPINE 200 MG TABLET has ranged from a low of $0.1122 (Jul 17, 2024) to a high of $0.2469 (Sep 13, 2017), with a median of $0.1506 per EA.
Are there cheaper alternatives to NEVIRAPINE 200 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of NEVIRAPINE 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEVIRAPINE 200 MG TABLET?
NEVIRAPINE 200 MG TABLET (NDC 00378405091) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.